Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

NCT02610127 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT02610127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02610127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Lead sponsor
Baxalta now part of Shire
Phase
Observational
Overall status
Completed
Start date
December 30, 2015
Completion date
June 7, 2019
Enrollment
53 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acquired hemophilia a